A nanoparticle formulation and a method of preparation thereof

IN598111BActive Publication Date: 2026-08-06INDIAN INST OF TECH BANARAS HINDU UNIV VARANASI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202411043077
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-06-03
Publication Date
2026-08-06
Estimated Expiration
2044-06-03

AI Technical Summary

Technical Problem

Current anticoagulant treatments for thrombosis, such as heparin and EDTA, face challenges including reversibility issues, non-specific targeting, and side effects like heparin-induced thrombocytopenia, while existing nanoparticles lack biocompatibility and efficient calcium chelation capabilities, necessitating the development of non-toxic, biocompatible nanoparticles for effective anticoagulation and anti-thrombotic properties.

Method used

A nanoparticle formulation comprising a polymer-stabilized inorganic complex with the chemical formula (Mx[Ny(C2O4)z]-P, where M is selected from certain metals and N from specific transition metals, stabilized by polymers like PVP, PEG, or PVCL, is developed, which prevents blood clotting and thrombus formation by acting as an anticoagulating agent with improved biocompatibility and renal clearance.

Benefits of technology

The nanoparticle formulation effectively inhibits blood clotting, exhibits anticoagulating properties, and is biocompatible, non-toxic, and cost-effective, with enhanced renal clearance and ease of excretion, demonstrating prolonged clotting times and reduced hemolysis, making it suitable for medical devices and treatments.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a nanoparticle formulation of an inorganic complex that is stabilized by a polymer and a method of preparation thereof. The nanoparticle formulation comprises a polymer-stabilized inorganic complex having a chemical formula (Mx[Ny(C2O4)z]-P). The nanoparticle formulation of the present invention is biocompatible, hemocompatible, and non-toxic in nature. The inorganic complex is stabilized by the polymer that acts as a template and stabilizing agent for the formation and long-term stabilization of the prepared nanoparticle formulation in preventing human blood from clotting and thrombus formation. The present invention provides the nanoparticle formulation with long-term stability for blood clot management and other blood-related diseases such as abnormal clotting and thrombosis.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTIONThe present invention relates to the field of nanoparticles. More particularly, the present invention relates to a nanoparticle formulation comprising of a polymer stabilized inorganic complex having a chemical formula, (Mx[Ny(C2O4)z]-P), and a method of preparation thereof. BACKGROUND OF THE INVENTIONThrombosis refers to the formation of a blood clot (partial or complete blockage) within blood vessels that the natural flow of blood. The ability of blood to flow freely in vessels relies on complex homeostasis that exists between blood cells (including platelets), plasma proteins, coagulation factors, inflammatory factors, cytokines, and the endothelial lining within the lumen of arteries and veins. When there is an imbalance with this physiologic process, there can be an increased risk of developing a thrombosis versus a coagulopathy (increased risk of bleeding). Thrombosis and blood clot-related diseases pose significant global challenges, affecting millions of individuals and straining healthcare systems worldwide. These conditions, characterized by the formation of abnormal blood clots within blood vessels, may often lead to severe complications such as stroke, heart attack, and pulmonary embolism.The most common and effective treatments for thrombosis are medications called anticoagulants that prevent the formation of new blood clots. Usually, a person receives injectable anticoagulants, such as heparin or low-molecular-weight heparin. These medications begin working within hours. Long-term treatment for thrombosis typically involves medications called direct oral anticoagulants. People who are unable to take anticoagulants may instead undergo surgery to have a filter placed inside the vena cava, which is a large vein in the abdomen. The filter prevents any blood clots from traveling to the heart and lungs. However, people taking anticoagulants have an increased risk of excessive bleeding. Furthermore, the commonly used anticoagulants such as EDTA (ethylenediaminetetraacetic acid) and heparin face challenges related to their reversibility. The limitation ofEDTA in anticoagulation is its inability to target specific clotting factors and essential bivalent cations, whereas heparin leads to heparin-induced thrombocytopenia (HIT), a condition where the body forms antibodies against heparin-bound platelets, leading to a paradoxical increase in thrombotic events. Moreover, this increase in thrombotic events results in excessive bleeding and other diseases, including osteoporosis and skin-related diseases. Research is exploring nanoparticles as anti-coagulants or carry anticoagulant drugs to limit other pathological conditions involving coagulation.CN101899161 discloses a preparation method for polyethylene glycol (PEG)-modified ferric oxide nano-probe comprising the following steps: using a polymer with a plurality of carboxyl groups and ferric oxide nanoparticles to react; and utilizing the carboxyl groups on the surface of ferric oxide nanoparticles and diamino-terminated polyethylene glycol to react under the catalysis of 1,3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride and N-hydroxyl succinimide and prepare the PEG-modified ferric oxide nano-probe. However, the nanoparticles of the cited document are limited by the fact that amino polyethylene glycol modifies the surface of iron oxide nanoparticles at high density so that the iron oxide nanoparticles have protein nonspecific adsorption resistance and are enriched on tumor parts. The nanoparticles of the citation lack a chelating effect with the calcium ions, thus being unable to impair the coagulation pathway. CN116689775 disclosed a method of preparation of chiral bimetallic nanoparticle that comprises the steps under the protection of an inert atmosphere, uniformly stirring an alcohol solution of metal salt A and an alkaline alcohol solution of polyvinylpyrrolidone, stirring and reacting for 1-5 hours at 80-150°C, cooling to room temperature, adding an alcohol solution of metal salt B, uniformly stirring, continuously stirring and reacting for 1-5 hours at 80-150°C, centrifuging, and washing to obtain bimetallic nanoparticles; mixing and stirring the bimetal nanoparticles and chiral ligand molecule solution for 1-3 hours, and obtaining chiral bimetal nanoparticles after dialysis purification and separation. However, the cited document provides a chiral bimetallic nanoparticle that cannot be substituted by other organic metals, thereby limiting its applications.EP2461834 disclosed a blood pool contrast agent comprising very small iron oxide nanoparticles coated with poly (ethylene glycol) (PEG) based ligands. However, the cited document discloses nanoparticles that are biologically incompatible.WO2022260366 disclosed a Prussian blue / polyvinylpyrrolidone nanoparticle composite for removal of reactive oxygen species and use thereof, having biocompatibility and stable anti-oxidative efficacy. However, the cited document discloses toxic ligand cyanide in the inorganic complex, which does not chelate calcium efficiently, thus lacking anti-thrombosis and anti-coagulative properties.Saritha A. et al. 2015, Advanced Powder Technology, 26(2), 349-354, https: / / doi.org / 10.1016 / j.apt.2014.11.005 disclosed a facile, nontoxic and inexpensive synthesis of four different iron oxide nanoparticle polymorphs via the solid-state thermolysis of an inorganic chiral, 3D anhydrous K3[Fe(C2O4)3] precursor material. However, the cited document discloses non chelating ferric oxide nanoparticle that fails to chelate with the calcium ions thus lacking anti-thrombosis and anti-coagulative properties. Seo K et al. 2018, Materials letters, 215, 203-206, https: / / doi.org / 10.1016 / j.matlet.2017.12.107 disclosed the effects of PVP on the formation of iron oxide nanoparticles produced by polyol synthesis. Iron oxide nanoparticles were synthesized in ethylene glycol, without PVP and with PVP. However, further research is needed to provide non-toxic and biocompatible nanoparticles that can be stabilized by a polymer such as PVP.Therefore, there is a need to develop non-toxic, biocompatible nanoparticles for preventing nanoparticle aggregation as well as a comprehensive approach to alleviate the serious complications that arise due to thrombosis.OBJECT OF THE INVENTION The main object of the present invention is to provide a nanoparticle formulation of an inorganic complex that is stabilized by a polymer.Another object of the present invention is to provide a method of preparation of the nanoparticle formulation.Yet another object of the present invention is to provide a biocompatible, hemocompatible, and non-toxic formulation having nanoparticles of smaller size that aid in improved blood circulation and further help in renal clearance and easy excretion.Yet another object of the present invention is to provide a cost-effective nanoparticle formulation that is water soluble, crystalline in nature, and easy to prepare.Still another object of the present invention is to provide a nanoparticle formulation that has an anticlotting effect and possesses efficient anticoagulation and anti-thrombotic properties.SUMMARY OF THE INVENTIONThe present invention relates to a nanoparticle formulation comprising of an inorganic complex that is stabilized by a polymer (P) acting as a template and stabilizing agent for the formation and long-term stabilization of the prepared nanoparticles in preventing human blood from clotting and thrombus formation.In an embodiment, the present invention provides a nanoparticle formulation comprising of a polymer stabilized inorganic complex having chemical formula, (Mx[Ny(C2O4)z]-P). The M is selected from K, Ca, Ba, Mg, Na, Li, Be, Rb, Sr, Cs or Fr; N is selected from Fe, Co, Ni, Zn, Cu, Mn, Sc, Ti, V, Cr, Ga, Cd, Ag, Au, Pt, Ru, Rh or Pd; x is having a value ranging from 0.1 to 3; y is having a value ranging from 0.1 to 1; z is having a value ranging from 0.1 to 3; and the polymer (P) is a stabilizing polymer in a range of 0.1-1.0% and is selected from poly-N-vinylpyrrolidone (PVP), polyethylene glycol (PEG200, PEG400, PEG800) or polyvinyl caprolactam (PVCL).In another embodiment, the present invention provides a method for preparation of a nanoparticle formulation of a polymer stabilised inorganic complex having a chemical formula, (Mx[Ny(C2O4)z]-P) comprising the steps of: (a) adding 1-10 g of ferrous sulphate (FeSO4) and 1-20 g of barium oxalate in 20-100 mL of miliQ water followed by adding 50-500 mg of a polymer to obtain a mixture; (b) stirring the mixture obtained in step (a) on a magnetic stirrer at 400-500 rpm for 5-60 minutes followed by adding 1-20 g of potassium oxalate, stirring for 5-60 minutes and adding a solution of 1-20 mL of a solubilizing agent and stirring for 5-60 minutes to obtain a reaction mixture; (c) heating the reaction mixture obtained in step (b) on a steam bath at a temperature range of 15-80°C for 3-4 hours with occasional stirring of 2-3 minutes after a gap of 10-60 minutes followed by cooling to room temperate and filtering the reaction mixture by filter paper to obtain a filtrate; (d) adding the filtrate obtained in step (c) in centrifuge tubes with 10-60 mL of ethanol and centrifuging at 1000-8000 rpm at 20-30°C for 10-60 minutes followed by removing supernatant to obtain precipitates; and (e) washing the precipitates obtained in step (d) with ethanol and drying the precipitates in air to obtain a nanoparticle formulation.Here, the polymer in step (a) is selected from poly-N-vinylpyrrolidone (PVP), polyethylene glycol (PEG200, PEG400, PEG800), or polyvinyl caprolactam (PVCL). Further, said polymer in step (a) is preferably poly-N-vinylpyrrolidone (PVP), and the solubilizing agent in step (b) is N / 10 HCl.The present invention relates to a nanoparticle formulation of PVP-stabilized potassium ferric oxalate nanoparticles for blood clot management and other blood-related diseases such as abnormal clotting and thrombosis.The above objects and advantages of the present invention will become apparent from the hereinafter set forth brief description of the drawings, detailed description of the invention, and claims appended herewith.BRIEF DESCRIPTION OF THE DRAWINGSAn understanding of the nanoparticle formulation and the method of preparation thereof, of the present invention may be obtained by reference to the following drawings:Figure 1 is a pictorial representation of the prepared nanoparticle formulation (KFeOx-NPs) in part (a) and a pictorial representation of a molecule of potassium ferric oxalate nanoparticle stabilized by polyvinylpyrrolidone (PVP) in part (b), according to an embodiment of the present invention.Figure 2 is a graphical representation of the Fourier transform infrared (FTIR) spectroscopy analysis of the PVP (blue) and nanoparticles (NPs) (red) in part (a); a graphical representation of ultra-violet (UV) spectroscopy analysis of NPs showing absorbance at 262 nm in part (b); a graphical representation of X-ray diffraction (XRD) sharp peaks showing crystalline nature in part (c); a pictorial representation of SEM in part (d); a pictorial representation of TEM in part (e); a pictorial representation of SAED pattern in part (f); a graphical representation of EDAX and color mapping showing the presence of elements in KFeOx-NPs in part (g); and a graphical representation of DLS showing a size range of 200-400 nm in part (h), according to the present invention.Figure 3 is a pictorial representation of the results of the anticoagulating property of KFeOx-NPs in part (a), a graphical representation of prothrombin time in part (b), and a graphical representation of activated partial thromboplastin time in part (c), according to the present invention.Figure 4 is a pictorial representation of high-resolution microscopical images of smears showing blood cells at 60x in part (a); a pictorial representation of gel doc images of agarose plate assay at different time points in part (b); a pictorial representation of dynamic clotting time assay in part (c), according to the present invention.Figure 5 is a pictorial representation of the analysis of the area formed in agarose plate assay by ImageJ software, according to the present invention.Figure 6 is a pictorial representation of the absorbance of dynamic clotting time assay at 540 nm, according to the present invention.Figure 7 is a pictorial representation of microscopic images of untreated and KFeOx-NPs treated infectious chick embryo models at 0 and 6 hours in part (a); and a graphical representation of the quantification with respect to length, junction, endpoints, and size by ImageJ and Angiotool software in part (b), according to the present invention.Figure 8 is a graphical representation of the hemolysis assay showing % hemolysis less than 5%, according to the present invention.Figure 9 is a graphical representation of the cell viability assay, according to the present invention.Figure 10 is a schematic representation of the tail bleeding model, according to the present invention.Figure 11 is a graphical representation of the parameters analyzed from the in vivo assay, including clotting time in part (a), amount of blood in part (b), and optical density (OD) of blood at 540 nm in part (c), according to the present invention.Figure 12 is a schematic representation of the thrombosis model, according to the present invention.Figure 13 is a schematic representation of the process of the thrombosis model in part (a) and a pictorial representation of histology images of the femoral vein in part (b), according to the present invention.Figure 14 is a graphical representation of the histological parameter analyzed (area of thrombus) by ImageJ software, according to the present invention.Figure 15 is a graphical representation of the histological parameter analyzed (amount of leukocytes) by ImageJ software, according to the present invention. Figure 16 is a graphical representation of the histological parameter analyzed (amount of fibrin) by ImageJ software, according to the present invention.DETAILED DESCRIPTION OF THE INVENTIONThe present invention will now be described hereinafter with reference to the accompanying drawings in which a preferred embodiment of the invention is shown. This invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiment set forth herein. Rather, the embodiment is provided so that this disclosure will be thorough, and will fully convey the scope of the invention to those skilled in the art.The present invention now will be described hereinafter with reference to the detailed description, in which some, but not all embodiments of the invention are indicated. Indeed, the invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Like numbers refer to like elements throughout. The present invention is described fully herein with non-limiting embodiments and exemplary experimentation. The present invention provides a nanoparticle formulation comprising of an inorganic complex that is stabilized by a polymer (P) acting as a template and stabilizing agent for the formation and long-term stabilization of the prepared nanoparticles in preventing human blood from clotting and thrombus formation.In a preferred embodiment, the present invention provides a nanoparticle formulation comprising of a polymer stabilized inorganic complex having a chemical formula, (Mx[Ny(C2O4)z]-P) wherein, M is selected from K, Ca, Ba, Mg, Na, Li, Be, Rb, Sr, Cs or Fr; N is selected from Fe, Co, Ni, Zn, Cu, Mn, Sc, Ti, V, Cr, Ga, Cd, Ag, Au, Pt, Ru, Rh or Pd; x is having a value ranging from 0.1 to 3; y is having a value ranging from 0.1 to 1; z is having a value ranging from 0.1 to 3; and the polymer (P) is a stabilizing polymer in a range of 0.1-10% and is selected from poly-N-vinylpyrrolidone (PVP), polyethylene glycol (PEG200, PEG400, PEG800) or polyvinyl caprolactam (PVCL).Here, the nanoparticle formulation is an inorganic complex nanomaterial; the size of the nanoparticles is in a range of 100-1000 nm. The nanoparticle formulation ispreferably polyvinylpyrrolidone stabilized potassium ferric oxalate (KFeC2O4-PVP) and exhibits a negative zeta potential value ranging from +50 Mv to -50 Mv. Further, the nanoparticle formulation acts as an anticoagulating agent with a dose of 1-50 mg / mL that exhibits a prothrombin time (PT) in a range of 30 to 70 seconds and activated partial thromboplastin time (aPTT) in a range of 300 to 700 seconds; exhibits haemolysis % in a range of 1.07 to 0.17% and cell viability of 80-100% for a concentration range of 0.5 to 4 mg / mL. The optical density of the nanoparticle formulation ranges from 1.0 to 0.25 for a time period of 10-90 minutes at a wavelength of 540 nm and is crystalline in nature. Further, the nanoparticle formulation is water soluble and organic insoluble and possesses biocompatibility and hemocompatibility with doses in a range of 1-50 mg / mL.The nanoparticle formulation is non-toxic with cell lines including HUVEC (Human Umbilical Vein Endothelial Cells), HUVEC-L, HUVEC-S, NHDF (Normal Human Dermal Fibroblasts), HGF (Hepatocyte Growth Factor), HAEC (Human Aortic Endothelial Cells), HMEC (Human Mammary Epithelial Cells), HFF (Human Foreskin Fibroblasts), HBEpC (Human Bronchial Epithelial Cells), HUASMC (Human Umbilical Artery Smooth Muscle Cells), NHBE (Normal Human Bronchial Epithelial cells), HPASMC (Human Pulmonary Artery Smooth Muscle Cells), HRE (Human Renal Epithelial Cells), HUVEC-PCS. In addition, the nanoparticle formulation is infused with human blood for examination and is in the form of a medical device that is coated with a compound. The medical device is an implantable device, a cardiac pacemaker, a catheter, a needle injection catheter, a blood clot filter, a vascular transplant, a balloon, a stent transplant, a biliary stent, an intestinal stent, a bronchial stent, an oesophageal stent, a ureteral stent, an aneurysm-filling coil or other coil device, a surgical repair mesh, a breast implant, a silicone implant, PDMS, a transmyocardial revascularization device, a percutaneous myocardial revascularization device, a prosthesis, an organ, a vessel, an aorta, a heart valve, a tube, an organ replacement part, an implant, a fibre, a hollow fibre, a membrane, a textile, banked blood, a blood container, a titer plate, an adsorber media, a dialyzer, a connecting piece, a sensor, a valve, an endoscope, a filter, a pump chamber, or another medical device intended to havehemocompatible properties or used in cancer, diabetes, ischemia, anti-bacterial, haemophilia, stroke, blood disorder, or a cytokine therapy involving human engineered cells and is preferably a catheter. The nanoparticle formulation helps in the detection of haemoglobin, haematocrit, and other blood-related parameters and also helps in drug delivery for mRNA, rRNA, protein peptides, active pharmaceutical ingredients (APIs), targeting ligands, stimuli-responsive components, small molecule drugs, peptides, proteins, nucleic acids (such as DNA or RNA), and other biologically active compounds.In another preferred embodiment, the present invention provides a method for preparation of a nanoparticle formulation of a polymer stabilised inorganic complex having chemical formula, (Mx[Ny(C2O4)z]-P), comprising the steps of: (a) adding 1-10 g of ferrous sulphate (FeSO4) and 1-20 g of barium oxalate in 20-100 mL of miliQ water followed by adding 50-500 mg of a polymer to obtain a mixture; (b) stirring the mixture obtained in step (a) on a magnetic stirrer at 400-500 rpm for 5-60 minutes followed by adding 1-20 g of potassium oxalate, stirring for 5-60 minutes and adding a solution of 1-20 mL of a solubilizing agent and stirring for 5-60 minutes to obtain a reaction mixture; (c) heating the reaction mixture obtained in step (b) on a steam bath at a temperature range of 15-80°C for 3-4 hours with occasional stirring of 2-3 minutes after a gap of 10-60 minutes followed by cooling to room temperate and filtering the reaction mixture by filter paper to obtain a filtrate; (d) adding the filtrate obtained in step (c) in centrifuge tubes with 10-60 mL of ethanol and centrifuging at 1000-8000 rpm at 20-30°C for 10-60 minutes followed by removing supernatant to obtain precipitates; and (e) washing the precipitates obtained in step (d) with ethanol and drying the precipitates in air to obtain a nanoparticle formulation. Here, the polymer in step (a) is selected from poly-N-vinylpyrrolidone (PVP), polyethylene glycol (PEG200, PEG400, PEG800), or polyvinyl caprolactam (PVCL). Further, said polymer in step (a) is preferably poly-N-vinylpyrrolidone (PVP), and the solubilizing agent in step (b) is N / 10 HCl.Referring to Figure 1, a pictorial representation of the prepared nanoparticle formulation (KFeOx-NPs) in part (a), and a pictorial representation of a molecule of potassium ferric oxalate nanoparticle stabilized by polyvinylpyrrolidone (PVP) in part (b), is depicted.EXAMPLE 1 For Experimentation DataMaterials and MethodsA polymer, PVP as a stabilizing agent and a solution of HCL (N / 10) as a solubilizing agent is taken for the preparation of the nanoparticle formulation. PVP helps to prevent the aggregation or agglomeration of nanoparticles. PVP adsorbs onto the surface of nanoparticles, creating a protective layer that reduces the likelihood of particles coming into direct contact and sticking together, as depicted in part (b) of Figure 1. The presence of PVP also contributes to the overall stability of nanoparticle formulations by preventing particle settling, precipitation, or flocculation. The stability is crucial for the shelf life and performance of nanoparticle-based products. Further, the solution of HCl (N / 10) serves as a solubilizing agent to lower the pH. The chemical functionality of KFeOx-NPs was characterized through the FTIR. The crystalline nature of NPs was checked through the XRD. The average particle size and zeta potential of NPs were determined by dynamic light scattering (DLS) by dispersing the nanoparticles into water. HR-TEM was employed to examine the particle shape and size. PT and aPTT tests were performed to confirm the anticoagulating properties of nanoparticles. The result shows that the blood containing NPs takes a longer time to form the clot. Further, a tail bleeding anticoagulant model in BALB / C mice was conducted for the anticoagulation property analysis. The amount of blood, clotting time, and OD of blood obtained were recorded. The analysis showed that NPs have longer clotting time than untreated and commercially used heparin. A ferric chloride-induced thrombosis model was generated in BALB / C mice for in vivo study of thrombosis. The mice were treated intravenously with NPs and comparedwith the control and heparin-treated group. The NP-treated group showed no formation of thrombi. Animal ethical committee approval (for BALB / C mice): IIT(BHU)IAEC / 2023 / 11 / 075. Ethical clearance for Human blood samples: ECR / 526 / Inst. / UP / 2014 / RR-20.Method for preparation Initially, 2.5 gm of ferric sulfate was mixed with 60 ml miliQ water, and 5 gm of barium oxalate was added to the reaction mixture in the presence of 250 mg of PVP (polyvinyl pyruvate) followed by stirring on the magnetic stirrer for 30 mins at 400-500 RPM in the room temperature condition. 2.7 gm of potassium oxalate was added and stirred again for 15 minutes under room temperature, and 4 ml of HCl (N / 10) was added under room temperate stirring for 15-20 minutes. Thereafter, the reaction mixture was transferred to a steam bath for 3-4 hours with occasional stirring, and the obtained reaction mixture was filtered through filter paper. The obtained filtrate was transferred equally to 4 centrifuge tubes with 20 ml of ethanol for centrifugation at 25 degrees Celsius and 6500 rpm for 30 minutes until the color changes and a precipitate was obtained at the bottom. The supernatant was discarded, and the precipitate was washed with ethanol twice for (30 minutes cycle each) in the same centrifuged condition. After washing with ethanol, the obtained precipitate was air dried to finally obtain the potassium ferric oxalate nanoparticles (KFeOx-NPs). EXAMPLE 2CharacterizationFourier-transformed infrared spectroscopy (FTIR)The functional groups present in the KFeOx-NPs were characterized by the stretching and bending frequencies in the FTIR spectra. FTIR spectra were recorded with the help of Nicolet iS5 (THERMO Electron) in IIT (BHU). The solid nanoparticles were taken for FTIR analysis.Figure 2 shows the thorough characterization of KFeOx-NPs. Part (a) of Figure 2 displays the FTIR analysis of KFeOx-NPs (red) and PVP (blue), showing distinctIR peaks. The major IR stretching frequencies observed in 3443.27, 2926.93, 1685.96, 1399.10, 1272.78, 892.39, and 803.20, while the peaks for PVP were 3435.08, 2964.05, 1674.39 and 1295.93. Upon investigating the FTIR spectra of KFeC2O4-PVP NPs corresponding to PVP, significant shifts in peak positions were observed, which is reasonably attributed to the reduction, capping, and stabilization processes during the synthesis of NPs. The peak at 3435.08 corresponds to -OH stretching, which went to 3443.27, demonstrating the role of PVP in the formation and stabilization of KFeC2O4-PVP NPs. Similarly, the band at 2926.93 and at 2964.05 was associated with the (C-H) stretching and helps in the stabilization of NPs. The band around 1674.39 was shifted to 1685.96, suggesting the involvement of (C=O) in the NPs synthesis. The peak at 1399.10 is associated with the (S=O) stretching due to the presence of sulfur in the precursor (ferric sulfate). The peak at 1295.93 underwent to 1272.78, which corresponds to (C-O) stretching. The peaks at 892.39 and 803.20 suggest the involvement (C-H) stretching during the preparation of KFeOx- NPs. UV-visible spectroscopyThe ultraviolet and visible absorption spectrum of KFeOx-NPs was recorded with UV-visible spectroscopy by a Bio spectrometer (Eppendorf) in a quartz cuvette at a wavelength range of 800 nm to 200 nm with a resolution of 1 nm. Part (b) of Figure 2 represents the ultraviolet spectroscopy (UV) absorption peak of the synthesized NPs, which was detected at approximately 262 nm.X-ray diffraction (XRD) methodThe greenish pellets of synthesized KFeOx-NPs samples were obtained by centrifugation at 6500 rpm at 25°C for 45 minutes in Eppendorf centrifuge 5430 R. The glass slide was coated with the loose KFeOx-NPs pellet by air drying the solvent repeatedly and submitted for XRD analysis. The structure and phase purity of the as-synthesized KFeOx-NPs samples were determined by X-ray diffraction method with the help of Rigaku SmartLab 9kW Powder type (without χcradle) (RIGAKU Corporation).X-ray diffraction pattern of KFeOx-NPs exhibits distinct peaks at 2θ positions, as depicted in part (c) of Figure 2. The XRD analysis confirms that the crystal structure of KFeOx-NPs is in the face-centered cubic (FCC) configuration and hence, supports the SAED pattern, as shown in part (f) of Figure 2.Scanning electron microscopy (SEM) SEM analysis by Nova Nano SEM 450 (FEI Company of USA (S.E.A.) PTE, LTD) elemental analysis and color mapping depending on the SEM images were analyzed by Team Pegasus Integrated EDS-EBSD with Octane Plus and Hikari Pro (EDAX Inc.)The SEM analysis shows the structure and morphology of the nanoparticles. Energy-dispersive X-ray analysis (EDAX) and color mapping from SEM confirm the presence of potassium (K), iron (Fe), carbon (C), oxygen (O), and sulfur (S) elements in the synthesized NPs, as shown in part (g) of Figure 2. Further, inductively coupled plasma mass spectrometry (ICP-MS) was analyzed to determine the Fe concentration that was observed to be 0.856 mg in a 2 mg / ml sample.Transmission electron microscopy (TEM)For the analysis of shape, the size and the structural morphology of the chemically synthesized KFeOx-NPs were characterized by a Tecnai G2 20 TWIN (FEI Company of USA (S.E.A.) PTE, LTD). 1 mg / ml KFeOx-NPs in miliQ was drop cast on a copper grid for the analysis. From the images obtained, unique morphology was observed. SAED was characterized by the same.Scanning electron microscope (SEM) analysis of KFeOx-NPs is represented in part (d) of Figure 2, showing a circular structure of NPs, which is confirmed in transmission electron microscopy (TEM) analysis, as shown in part (e) of Figure 2 and the size of NPs is found between the range of 200 to 300 nm.Dynamic light scattering (DLS)The average size of the synthesized KFeOx-NPs was calculated by taking a solution of 2 mg / ml of as-synthesized KFeOx-NPs in the sample chamber for the measurement of the size. The zeta potential of a solution of KFeOx-NPs was measured in a zeta potential analyzer (Malvern) in a quartz cuvette by taking 2 mg of KFeOx-NPs in 1 mL of deionized water. Dynamic Light Scattering (DLS) was employed to access the size and charge of KFeOx-NPs, as shown in part (h) of Figure 2. DLS shows a wide range of 200-400 nm and a zeta potential value of -16.77; the negative value indicates stable nanoparticle formation without any aggregation. The size measurements obtained in TEM are consistently smaller in comparison to the results from DLS. Overall, the negative zeta potential is a crucial factor contributing to the long-term stability of NPs and the effective dispersion of the synthesized NPs.EXAMPLE 3Anticoagulation propertyIn vitro anticoagulation assay To determine the anticoagulation property of KFeOx-NPs, prothrombin time (PT), activated partial thromboplastin time (aPTT), dynamic clotting time, and agarose plate assay were accomplished. Human blood samples were taken to conduct all studies, and the approval of the ethical committee was obtained from the Institute of Medical Sciences, Banaras Hindu University (Ref. No. ECR / 526 / Inst. / UP / 2014 / RR-20 date- May 19, 2020).Prothrombin time (PT) and activated partial thromboplastin time (aPTT) tests were carried out in Ankuram PathLab. 100 μl of plasma from centrifuged blood was taken and was added with the respective PT and aPTT reagents along with calcium chloride (CaCl2) solution, and finally diagnosed with Thrombostat 1 (Behnk Elektronik).For the agarose plate assay, 350 mg of agar was mixed and heated with 5 ml (0.025 mol / L) calcium chloride (CaCl2) until a clear solution was obtained. An equalamount of plasma (from blood containing EDTA and KFeOx-NPs was added to the agar solution (1:1 ratio). The obtained mixture was transferred to the well plate and incubated at 37°C until the film was formed. After the film was formed, a well of 1cm diameter was created, and a solution of 20 μl kaolin (1 mg / ml) was added to the wells and observed at different time points 0, 6, 20, and 24 hours by Syngene G:BOX Gel Doc. The zone formed was analyzed by the ImageJ software.In the dynamic clotting time assay, 100 μl of blood (untreated, blood with EDTA, blood with KFeOx-NPs) was added to a 6-well plate. Immediately, a solution of 10μL of 0.2 M CaCl2 was added, and incubated for 10, 60, and 90 minutes. The samples were washed with MiliQ water for 1 minute, and the absorbance of the washed solution was detected at 540 nm in the microplate reader (Synergy H1-Microplate reader).The Anticoagulation property of KFeOx-NPs was evaluated by taking a healthy human blood sample and compared with untreated and positive control as EDTA, as shown in part (a) of Figure 3. Visual observation suggests that NPs prevent the blood from clotting. The observation confirms that a solution of 2 mg / ml of KFeOx-NPs shows an anticlotting effect. PT and aPTT are well-established commercial standards to evaluate clotting time. Blood containing KFeOx-NPs shows more amount of time to clot than commercial standard EDTA, as shown in part (b) of Figure 3b. A general range for PT in the blood is usually around 11 to 13 seconds, which gets extended due to the addition of anticoagulants. If PT values are prolonged, the NPs are effectively interfering with the extrinsic coagulation cascade, resulting in a delay in clot formation. Similarly, aPTT values are more for blood containing KFeOx-NPs NPs, as shown in part (c) of Figure 3, the general range for aPTT in blood samples is typically around 25 to 35 seconds. The prolonged aPTT values suggest effective interference with the intrinsic pathway of the coagulation cascade as primarily assessed by the aPTT. Part (a) of Figure 4 represents a microscopical examination of blood containing EDTA and KFeOx-NPs compared to untreated. Smears of blood were made by taking leishman stain and observed under a high-tech microscope (60x). The microscopical evaluation confirms no morphological changes at the cellular level in the blood and suggeststhat the synthesized NPs do not show any change in the cellular morphology of the blood. Agarose plate assay was further used to evaluate the anticoagulation activity, as shown in part (b) of Figure 4. Kaolin is often employed as an additive to promote clotting, similar to thrombin. When added to blood plasma, kaolin activates the intrinsic pathway of the coagulation cascade, leading to the formation of a fibrin clot. The formation of a clear area zone surrounding the well depicts the fibrinolytic activity of the KFeOx-NPs. As fibrin is essential for clot formation, the lysis of fibrin leads to promoting the anticoagulating properties. The zone was calculated and plotted with the help of ImageJ software, as shown in Figure 5. Dynamic clotting time of KFeOx-NPs with EDTA and control sample are shown in part (c) of Figure 4. The optical density of KFeOx-NPs in all time points is greater than EDTA and control samples, as shown in Figure 6. The observation shows more concentration of free blood in the sample containing KFeOx-NPs, resulting in the lysis of hemoglobin. Thus, KFeOx-NPs show more clotting time in CaCl2-induced clotting assay. The OD was statistically plotted with the help of ANOVA.Biocompatibility AssayThe Chorioallantoic Membrane (CAM) assay is an extensively researched in ovo assay to assess biomaterials before being further examined in animal models. The CAM assay is a transient platform for investigating the angiogenic potential and evaluating the safety and biocompatibility of the desired sample. The CAM assay was performed to examine the impact of KFeOx-NPs on the development of blood vessels. Fertilized eggs were first acquired from the Patel Poultry Farm in Varanasi, Uttar Pradesh. The acquired eggs were incubated at 37°C for 4 days. After the incubation phase, a small hole was carefully created on the eggshell to monitor the growth of the developing embryo. 6 mm Whatman filter paper (discs) was soaked with a mixture containing KFeOx-NPs (2 mg / ml) for a few seconds. The discs were subsequently placed above the CAM layer. At this early time, the images were captured employing Mgnus MagZoom TZM6 Trinocular Stereo Zoom Microscope. The eggs were now sealed with the help of parafilm and placed backin the incubator for another six hours. Additional images were taken after 6 hours and 24 hours to measure the fold change in different parameters. As a point of comparison, untreated eggs were employed. Quantification of the microscopic images was done by Angiotool and ImageJ software.Through a stereo microscope, blood vessel images of chick embryos were taken at various points up to six hours after treatment. According to the results shown in part (a) of Figure 7, KFeOx-NPs treatment did not prevent blood vessels from forming or damage vascular networks in chick embryos. Fold changes in different parameters, including area, junctions, length, and endpoints, were quantified employing Angiotool and ImageJ software, as shown in part (b) of Figure 7. The analysis results indicated that in both the treated and untreated samples, the fold change in area, length, and endpoints remained nearly constant. In contrast to the untreated sample, there is a rise in the fold change in the junction parameters. Hence, the synthesized KFeOx-NPs are biocompatible and safe for biomedical applications. Hemolytic AssayFresh human blood was collected and centrifuged at 3000 rpm for 15 minutes to check the hemocompatibility of the KFeOx-NPs. The settled red blood cells (RBC) were washed trice with phosphate buffer saline (PBS). In 900 μl of PBS, 50 μl of separated RBC was added and treated with the remaining 50 μl of the sample at different concentrations (0.5, 1, 2, 4, and 8 mg / ml KFeOx-NPs). The prepared samples were incubated in shaking condition for 4 hours. The supernatant's optical density (OD) after centrifugation was measured at 540 nm in the microplate reader (Synergy H1-Microplate reader). The haemolysis rate was calculated by the following formula: Haemolysis %=OD(Sample)-OD(Negative control)OD(Positive control)-OD(Negative control) x 100Hemolytic assay shows the hemocompatibility of the prepared NPs when treated with RBC. By measuring the extent of red blood cell lysis caused by the NPs, the safety profile was evaluated. Hemolysis assay help assess the biocompatibility of materials with blood, by measuring the amount of hemoglobin released at 540 nm. The hemolysis % for toxicity measurement is 5%. The hemolysis % for the optimized dose of 2 mg / ml was found to be 0.15%, as shown in Figure 8. The result indicates the compatibility of KFeOx-NPs with blood, especially RBC. The OD for all concentrations was statistically plotted by ANOVA.In-vitro cytotoxicity study (Cell viability assay)Cell viability assay (MTT) by taking HEK cells (Human normal kidney cells) was performed to ensure the non-toxic nature (nearly 120% cell viability for 2 mg / ml dose of NPs), similarly, hemolysis assay was conducted to check the effect on blood (0.15% for 2 mg / ml dose of NPs), especially on RBC ensuring that NPs are not toxic to blood as less than 0.5% of optical density (OD) of hemoglobin was obtained. Time-dependent (0, 6, and 24 hours) blood smear analysis through a hi-tech pathological microscope also shows no changes in the morphology of blood cells. MTT (3-(4, 5-dimethyl thiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay is a colorimetric method employed to evaluate the cytotoxicity of any substance. When mitochondrial dehydrogenase enzymes are active, the MTT reagent forms formazan crystals, which turn purple from yellow by adding DMSO. Human embryonic kidney cells (HEK-293 cell line) cultured in 96 well plate (10,000 cells / well) were incubated for 24 hours. The cultured cells were treated with KFeOx-NPs at different doses (0.5, 1, 2, 4, and 8 mg / ml) with further 24-hour incubation. 100 μl of MTT reagent in DMEM (0.5 mg / ml) was added to each well by replacing the previous media. After 4 hours of MTT, DMSO was added to solubilize the formazan crystals. The purple color change was measured in the microplate reader (Synergy H1-Microplate reader) at 570 nm. The viability was calculated as: Cell viability (%)= Absorbance of sampleAbsorbance of control x 100Cell viability was tested in human embryonic kidney cells (HEK-293 cell line) for 24 hours to evaluate the effect of KFeOx-NPs in the in-vitro toxicity at different doses (0.5, 1, 2, 4, 8 mg / ml), as shown in Figure 9. The results confirm that KFeOx-NPs at 2 mg / ml concentration show maximum cell viability compared to other concentrations and controls, and the observation proves the non-toxic nature of the prepared nanoparticles for biological application.Mouse tail bleeding in vivo modelThe mouse tail-cutting bleeding model was performed to evaluate the anticoagulation potential of KFeOx-NPs. Following clearance of the anticoagulating potential of nanomaterial / biomaterials for blood clot management by the Institutional Animals Ethics Committee (IAEC) of Indian Institute of Technology, BHU, Varanasi approval ID: IIT(BHU) / IAEC / 2023 / II / 075 has carried out all in vivo investigations. BALB / C mice were intravenously injected with KFeOx-NPs and heparin In vivo (1 mg / ml). After one hour of treatment, the mice were anesthetized, and the tail (4-5 cm above the tip) was amputated. Parameters including clotting time, amount of blood, and optical density of obtained blood were measured at 540 nm in the microplate reader (Synergy H1-Microplate reader).Mouse tail bleeding is extensively employed as an in vivo method to determine bleeding-related aspects of an antithrombotic drug and drug products. BALB / C mice were injected with heparin and KFeOx-NPs one hour prior to the experiment, as shown in Figure 10. After the tail cut, measuring bleeding time in animals is mainly done to evaluate the haemorrhagic characteristics of anti-clotting drugs. the clotting time measured was more for KFeC2O4-PVP NPs compared to commercial control heparin and untreated groups, as shown in part (a) of Figure 11. Prolonging clotting time indicates the delay in the clot formation process due to the addition of an anticoagulant in the blood. The amount of blood ejected was collected and weighed, as shown in part (b) of Figure 11. Also, the optical density for the same was measured, as shown in part (c) of Figure 12, and plotted statistically by ANOVA.FeCl3-induced venous thrombosis modelThe BALB / C mice were anesthetized after an hour of treatment (intravenous 1 mg / ml of heparin and KFeOx-NPs). An incision was made, and a femoral vein was selected for this chemically induced model. The vein was introduced with Whatman filter paper (discs) soaked in FeCl3 solution for 3 minutes and removed. The vein was dissected out and histology was done. The ferric chloride-induced model was employed to study the thrombosis in the femoral vein. Figure 12 shows the process that was followed to conduct the in vivo experiment in BALB / C murine model. After the intravenous injection of KFeOx-NPs for 1 hour, the femoral vein was exposed and applied with a 10% solution of FeCl3 for 3 minutes. The blood perfusion or thrombus formation at injured veins was monitored by histology through H&E staining, as shown in part (b) of Figure 13. The microscopical analysis of histology suggests a potent inhibition effect in the femoral vein for thrombosis in the KFeOx-NPs treated group. Parameters related to thrombus formation were analyzed by ImageJ software, including the area of thrombus forms, RBC accumulation, leukocytes, and fibrin. The amount of accumulated RBC was observed more for the heparin-treated group than KFeOx-NPs, as shown in Figure 14. The presence of leukocytes indicates the occurrence of an immune reaction; when FeCl3 is induced, the veins and related components get chemically induced; hence, leukocyte accumulation occurs if a blood clot or thrombus formation takes place, as shown in Figure 15. Similarly, blood clot occurs due to the formation of fibrin. The fibrin was evaluated and plotted, as shown in Figure 16, statistically by ANOVA.Therefore, the present invention provides a cost-effective, biocompatible, hemocompatible, and non-toxic nanoparticle formulation of an inorganic complex that is stabilized by a polymer (P) for preventing human blood from clotting and thrombus formation.Many modifications and other embodiments of the invention set forth herein will readily occur to one skilled in the art to which the invention pertains, having the benefit of the teachings presented in the foregoing descriptions and the associateddrawings. Therefore, it is to be understood that the invention is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

Claims

1. A nanoparticle formulation comprising of a polymer stabilized inorganic complex having a chemical formula: (Mx[Ny(C2O4)z]-P), wherein, M is selected from K, Ca, Ba, Mg, Na, Li, Be, Rb, Sr, Cs or Fr; N is selected from Fe, Co, Ni, Zn, Cu, Mn, Sc, Ti, V, Cr, Ga, Cd, Ag, Au, Pt, Ru, Rh or Pd; x is having a value ranging from 0.1 to 3; y is having a value ranging from 0.1 to 1; z is having a value ranging from 0.1 to 3; and the polymer (P) is a stabilizing polymer in a range of 0.1-10% and is selected from poly-N-vinylpyrrolidone (PVP), polyethylene glycol (PEG200, PEG400, PEG800) or polyvinyl caprolactam (PVCL).

2. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation is an inorganic complex nanomaterial.

3. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation has M as Potassium (K), N as Iron (Fe), and P as PVP (poly-N-vinylpyrrolidone).

4. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation is preferably polyvinylpyrrolidone stabilized potassium ferric oxalate K3[Fe(C2O4)]3-PVP.

5. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation is crystalline and water soluble in nature.

6. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation exhibits the size of nanoparticles in a range of 100-1000 nm.

7. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation exhibits a negative zeta potential value ranging from +50 Mv to -50 Mv.

8. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation acts as an anticoagulating agent with a dose of 1-50 mg / mL that exhibits a prothrombin time (PT) in a range of 30 to 70 seconds and activated partial thromboplastin time (aPTT) in a range of 300 to 700 seconds.

9. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation possesses hemocompatibility with doses in a range of 1 to 50 mg / mL.

10. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation possesses biocompatibility with doses in a range of 1 to 50 mg / mL.

11. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation is non-toxic with cell lines including HUVEC (Human Umbilical Vein Endothelial Cells), HUVEC-L, HUVEC-S, NHDF (Normal Human Dermal Fibroblasts), HGF (Hepatocyte Growth Factor), HAEC (Human Aortic Endothelial Cells), HMEC (Human Mammary Epithelial Cells), HFF (Human Foreskin Fibroblasts), HBEpC (Human Bronchial Epithelial Cells), HUASMC (Human Umbilical Artery Smooth Muscle Cells), NHBE (Normal Human Bronchial Epithelial cells), HPASMC (Human Pulmonary Artery Smooth Muscle Cells), HRE (Human Renal Epithelial Cells), HUVEC-PCS.

12. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation is infused with human blood for examination.

13. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation is in the form of a medical device that is coated with a compound.

14. The nanoparticle formulation as claimed in claims 1 and 13, wherein said medical device is an implantable device, a cardiac pacemaker, a catheter, a needle injection catheter, a blood clot filter, a vascular transplant, a balloon, a stent transplant, a biliary stent, an intestinal stent, a bronchial stent, an oesophageal stent, a ureteral stent, an aneurysm-filling coil or other coil device, a surgical repair mesh, a breast implant, a silicone implant, PDMS, a transmyocardial revascularization device, a percutaneous myocardial revascularization device, a prosthesis, an organ, a vessel, an aorta, a heart valve, a tube, an organ replacement part, an implant, a fibre, a hollow fibre, a membrane, a textile, banked blood, a blood container, a titer plate, an adsorber media, a dialyzer, a connecting piece, a sensor, a valve, an endoscope, a filter, a pump chamber, or another medical device intended to have hemocompatible properties or used in cancer, diabetes, ischemia, anti-bacterial, haemophilia, stroke, blood disorder, or a cytokine therapy involving human engineered cells.

15. The nanoparticle formulation as claimed in claims 1 and 13, wherein said medical device is a catheter.

16. The nanoparticle formulation, as claimed in claim 1, wherein said nanoparticle formulation detects hemoglobin, hematocrit, and other blood-related parameters.

17. The nanoparticle formulation as claimed in claim 1, wherein said nanoparticle formulation helps in drug delivery for mRNA, rRNA, protein peptides, active pharmaceutical ingredients (APIs), targeting ligands, stimuli-responsive components, small molecule drugs, peptides, proteins, nucleic acids (such as DNA or RNA), and other biologically active compounds.

18. A method for preparation of a nanoparticle formulation of a polymer stabilized inorganic complex of chemical formula (Mx[Ny(C2O4)z]-P) comprising the steps of: (a) adding 1-10 g of ferrous sulfate (FeSO4) and 1-20 g of barium oxalate in 20-100 mL of miliQ water followed by adding 50 to 500 mg of a polymer to obtain a mixture; (b) stirring said mixture obtained in step (a) on a magnetic stirrer at 400-500 rpm for 5-60 minutes followed by adding 1-20 g of potassium oxalate, stirring for 5-60 minutes again and adding a solution of 1-20 mL of a solubilizing agent and stirring for 5-60 minutes to obtain a reaction mixture; (c) heating said reaction mixture obtained in step (b) on a steam bath at a temperature range of 15-80°C for 3-4 hours with occasional stirring of 2-3 minutes after a gap of 10-60 minutes followed by cooling to room temperature and filtering the reaction mixture by filter paper to obtain a filtrate; (d) adding said filtrate obtained in step (c) in centrifuge tubes with 10-60 mL of ethanol and centrifuging at 1000-8000 rpm at 20-30°C for 10-60 minutes followed by removing supernatant to obtain precipitates; and (e) washing said precipitates obtained in step (d) with ethanol and drying said precipitates in the air to obtain a nanoparticle formulation.

19. The method as claimed in claim 18, wherein said polymer in step (a) is selected from poly-N-vinylpyrrolidone (PVP), polyethylene glycol (PEG200, PEG400, PEG800) or polyvinyl caprolactam (PVCL).

20. The method as claimed in claim 18, wherein said polymer in step (a) is preferably poly-N-vinylpyrrolidone (PVP) and the solubilizing agent in step (b) is N / 10 HCl.